Since our inception, Rx Bandz has been focused on providing an innovative next generation solution for patients who carry self injectable medication.
Rx Bandz Team
We have assembled a team of talented and experienced individuals who have the knowledge, skill and experience required to create the next innovative and disruptive auto-injector design capable of delivering a wide range of therapeutic injectable medications.
Jessica Walsh - Founder, CEO
Innovator and seasoned entrepreneur, former project manager for world-leading construction and engineering firm, business and technical experience from senior management positions in technology, business development, digital marketing, and team management, Six Sigma process improvements. Frustrated Epipen user.
Harsha Murthy – Chief Strategy Officer
Senior pharmaceutical executive with extensive experience in licensing to big pharma and direct experience with companies in the auto-injector space. Previous roles include founding private equity firms/funds (Consummate Capital and Konanda Pharma Partners) that invested in pharmaceuticals / medical devices, leadership roles at large and start-up pharmaceutical companies (King Pharmaceuticals and Eyetech Pharmaceuticals), financial industry (GE Capital, U.S. SEC and kRoad Ventures) and legal (Davis Polk & Wardwell and Latham & Watkins). B.A degree from Duke University and J.D. from Stanford Law School.
Myrna Walsh - Chief Administrative Officer
Former Executive Director of Massachusetts hospital system foundation. Published author. Successfully raised millions of dollars for healthcare in grants. Municipal capital budget advisory board member. Launched hospice from concept to Medicare ready. Frustrated EpiPen user.
James DeAngelis - Strategic Advisor
25 years of corporate financial experience in companies with environmental and biotech focus; 18 years as C-Level Executive with strategic development in intellectual property including manufacturing processes, laboratory analysis for early FDA approval applications, multi-million dollar exits and IPO.
Dr. Michael Blaiss MD, FACAAI - Chief Medical Officer
Clinical Professor of Pediatrics and Medicine, University of Tennessee Health Science Center. Executive Medical Director, American College of Allergy, Asthma, and Immunology. He was a past Medical Director for Pfizer and Merck.
Dr. Robert Carr MD, MPH, FACPM – Military Medical Advisor
Dr. Bob Carr is a retired AF flight surgeon and human performance /preventative medicine specialist. He was most recently the President of the American College of Preventive Medicine, and Senior Vice President & Corporate Medical Director at the global healthcare firm GlaxoSmithKline.
Perry Molinoff, MD. - Pharmaceutical Advisor
Dr. Molinoff's background includes more than thirty years of experience in both the academic and industrial sectors. He is professor of Pharmacology Emeritus, University of Pennsylvania. He is also Chairman of the Innovation Support Center Panel, Harrington Discovery Institute. Previously he directed research at Palatin Technologies and Bristol-Meyers Squibb Pharmaceutical Research Institute. He has served on the boards of multiple private and public pharmaceutical companies and published extensively, including six text books and over 230 manuscripts.
Julie DeAngelis Ph.D. - Health Economics Advisor
18 years diverse pharmaceutical experience with leadership positions within marketing, clinical development and health economics and outcomes research with Astellas Pharmaceuticals.
Obinna Anosike, MD- Medical Research
Rutgers Robert Wood Johnson Medical School. Held position as a M1 course facilitator
guiding learning, brainstorming, and problem solving of medical case based problems.
Masters in Biomedical Science DNJ-Stratford.
Stephen Harhen- Chief Engineering Officer
Bio-materials and mechanical engineer. He previously was a Research and Development Engineer for Ethicon, a Johnson and Johnson Company. He currently is a PhD candidate (Mechanical Engineering) at Villanova University and holds a MS (Biomedical Engineering) from New Jersey Institute of Technology, and a BS (Biomedical Engineering) from Rutgers University School of Engineering.
John Dines Dinesen - Chief Manufacturing Officer
Founder and President of IMSCE Engineering with more than 30 years engineering experience and 15 years within design, prototype, and building complex medical instruments and manufacturing systems in Europe, Asia and the US.
David Dlugo – Quality Management
Broad experience consulting on regulatory strategy and compliance. Editor of Biotech Daily Post for Medical Device/Combination Products/Pharma. Owner, D6 Product Development Consultants, guiding companies through product development in regulated environments. Oversees Technical Operation, US WorldMeds, managing combination products and medical devices, including compliance documentation. BS Mechanical Engineering.
Lori Baker MA – Quality Management
Over 20 years hands-on quality experience with GCP research and development; PK and toxicology GLP studies; commercial and investigational product GMP processes (compound/fill/labeling/packaging/serialization); and quality review of test method development with analysis of release and stability data. Dosage form knowledge with solution for injection, tablet, oral suspension and inhaled, along with drug/device combination delivery via single and multiple use auto- and manual injectors and nebulizer/vial system. FDA, ICH and EMA regulation-based audits on GXP vendors, clinical investigators and internal groups.
E Paul Harhen - Engineering Advisor
39 years experience in with engineering, medical device product design/testing for manufacture, support including clinical trials for FDA submission. Successfully developed numerous products and brought them to launch. Holds 28 US patent